Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death

Oelke, 2013, EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction, Eur Urol, 64, 118, 10.1016/j.eururo.2013.03.004 Hennenberg, 2014, Prostatic α1-adrenoceptors: New concepts of function, regulation, and intracellular signaling, Neurourol Urodyn, 33, 1074, 10.1002/nau.22467 Lukacs, 2013, Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study, Eur Urol, 64, 493, 10.1016/j.eururo.2013.02.026 MacDonald, 2012, Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review, BJU Int, 109, 1756, 10.1111/j.1464-410X.2012.11172.x Madersbacher, 2008, Plant extracts: sense or nonsense?, Curr Opin Urol, 18, 16, 10.1097/MOU.0b013e3282f0d5c8 Madersbacher, 2007, The long-term outcome of medical therapy for BPH, Eur Urol, 51, 1522, 10.1016/j.eururo.2007.03.034 Ventura, 2011, Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH), Br J Pharmacol, 163, 891, 10.1111/j.1476-5381.2011.01332.x Lee, 2011, Therapeutic applications of compounds in the Magnolia family, Pharmacol Ther, 130, 157, 10.1016/j.pharmthera.2011.01.010 Chan, 2008, Magnolol and honokiol account for the anti-spasmodic effect of Magnolia officinalis in isolated guinea pig ileum, Planta Med, 74, 381, 10.1055/s-2008-1034320 Ko, 2003, Inhibition of smooth muscle contraction by magnolol and honokiol in porcine trachea, Planta Med, 69, 532, 10.1055/s-2003-40654 Lu, 2003, The mechanism of honokiol-induced and magnolol-induced inhibition on muscle contraction and Ca2+ mobilization in rat uterus, Naunyn Schmiedebergs Arch Pharmacol, 368, 262, 10.1007/s00210-003-0802-8 Seok, 2011, Honokiol attenuates vascular contraction through the inhibition of the RhoA/Rho-kinase signalling pathway in rat aortic rings, J Pharm Pharmacol, 63, 1244, 10.1111/j.2042-7158.2011.01332.x Bian, 2006, Inhibitory effects of magnolol on distal colon of guinea pig in vitro, Biol Pharm Bull, 29, 790, 10.1248/bpb.29.790 Seok, 2012, Effects of magnolol on vascular contraction in rat aortic rings, Clin Exp Pharmacol Physiol, 39, 28, 10.1111/j.1440-1681.2011.05629.x Teng, 1990, EDRF-release and Ca+(+)-channel blockade by magnolol, an antiplatelet agent isolated from Chinese herb Magnolia officinalis, in rat thoracic aorta, Life Sci, 47, 1153, 10.1016/0024-3205(90)90176-R Zhang, 2013, Magnolol inhibits colonic motility through down-regulation of voltage-sensitive L-type Ca2+ channels of colonic smooth muscle cells in rats, Phytomedicine, 20, 1272, 10.1016/j.phymed.2013.07.008 Füllhase, 2013, Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms, Eur Urol, 64, 228, 10.1016/j.eururo.2013.01.018 Fan, 2014, Honokiol inhibits tumor necrosis factor-α-stimulated rat aortic smooth muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis, Inflammation, 37, 17, 10.1007/s10753-013-9707-y Hahm, 2008, Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction, Clin Cancer Res, 14, 1248, 10.1158/1078-0432.CCR-07-1926 Hahm, 2007, Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity, Mol Cancer Ther, 6, 2686, 10.1158/1535-7163.MCT-07-0217 Lee, 2006, Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells, FEBS Lett, 580, 5177, 10.1016/j.febslet.2006.08.064 Zhang, 2010, Effects of chronic treatment with honokiol in spontaneously hypertensive rats, Biol Pharm Bull, 33, 427, 10.1248/bpb.33.427 Timms, 2011, Prostate development and growth in benign prostatic hyperplasia, Differentiation, 82, 173, 10.1016/j.diff.2011.08.002 Lee, 2009, Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells, J Cell Biochem, 106, 1113, 10.1002/jcb.22098 Karki, 2013, Magnolol attenuates neointima formation by inducing cell cycle arrest via inhibition of ERK1/2 and NF-kappaB activation in vascular smooth muscle cells, Biochim Biophys Acta, 1830, 2619, 10.1016/j.bbagen.2012.12.015 Kim, 2007, Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells, Int Immunopharmacol, 7, 1083, 10.1016/j.intimp.2007.04.004 Wu, 2005, Elucidating the inhibitory mechanisms of magnolol on rat smooth muscle cell proliferation, J Pharmacol Sci, 99, 392, 10.1254/jphs.FP0050473 Chen, 2003, Magnolol induces apoptosis in vascular smooth muscle, Naunyn Schmiedebergs Arch Pharmacol, 368, 127, 10.1007/s00210-003-0779-3 Ho, 2012, Cardiovascular protection of magnolol: cell-type specificity and dose-related effects, J Biomed Sci, 19, 70, 10.1186/1423-0127-19-70 Arora, 2012, Honokiol: a novel natural agent for cancer prevention and therapy, Curr Mol Med, 12, 1244, 10.2174/156652412803833508 Zheng, 2013, Characterization, pharmacokinetics, tissue distribution and antitumor activity of honokiol submicron lipid emulsions in tumor-burdened mice, Pharmazie, 68, 41 Liang, 2014, Pharmacokinetics of honokiol after intravenous guttae in beagle dogs assessed using ultra-performance liquid chromatography-tandem mass spectrometry, Biomed Chromatogr, 10.1002/bmc.3179 Coulson, 2013, A phase II randomised double-blind placebo-controlled clinical trial investigating the efficacy and safety of ProstateEZE Max: a herbal medicine preparation for the management of symptoms of benign prostatic hypertrophy, Complement Ther Med, 21, 172, 10.1016/j.ctim.2013.01.007 Gerber, 2001, Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms, Urology, 58, 960, 10.1016/S0090-4295(01)01442-X Berges, 1995, Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia, Lancet, 345, 1529, 10.1016/S0140-6736(95)91085-9 Safarinejad, 2005, Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study, J Herb Pharmacother, 5, 1, 10.1080/J157v05n04_01 Lopatkin, 2005, Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms: a placebo-controlled, double-blind, multicenter trial, World J Urol, 23, 139, 10.1007/s00345-005-0501-9